Total Payments
$626,144
2024 Payments
$53,088
Companies
65
Transactions
2,213
Medicare Patients
966
Medicare Billing
$94,881
Payment Breakdown by Category
Other$385,757 (61.6%)
Consulting$156,163 (24.9%)
Food & Beverage$44,921 (7.2%)
Travel$38,863 (6.2%)
Education$440.45 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $385,757 | 174 | 61.6% |
| Consulting Fee | $156,163 | 36 | 24.9% |
| Food and Beverage | $44,921 | 1,809 | 7.2% |
| Travel and Lodging | $38,863 | 187 | 6.2% |
| Education | $440.45 | 7 | 0.1% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Biogen, Inc. | $230,510 | 378 | $0 (2024) |
| EMD Serono, Inc. | $119,744 | 249 | $0 (2024) |
| Genentech USA, Inc. | $44,284 | 104 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $42,236 | 168 | $0 (2024) |
| Celgene Corporation | $38,460 | 101 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $38,229 | 40 | $0 (2024) |
| GENZYME CORPORATION | $30,589 | 131 | $0 (2023) |
| TG Therapeutics, Inc. | $26,571 | 37 | $0 (2024) |
| Teva Pharmaceuticals USA, Inc. | $19,461 | 97 | $0 (2024) |
| Janssen Pharmaceuticals, Inc | $11,846 | 32 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $53,088 | 264 | TG Therapeutics, Inc. ($26,265) |
| 2023 | $42,696 | 275 | EMD Serono, Inc. ($13,037) |
| 2022 | $62,296 | 253 | Biogen, Inc. ($22,945) |
| 2021 | $36,805 | 183 | Biogen, Inc. ($25,210) |
| 2020 | $59,272 | 199 | Biogen, Inc. ($29,345) |
| 2019 | $137,535 | 227 | EMD Serono, Inc. ($48,560) |
| 2018 | $124,107 | 426 | Biogen, Inc. ($48,163) |
| 2017 | $110,346 | 386 | Biogen, Inc. ($46,105) |
All Payment Transactions
2,213 individual payment records from CMS Open Payments — Page 1 of 89
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/20/2024 | Celgene Corporation | ZEPOSIA (Drug) | Consulting Fee | Cash or cash equivalent | $2,400.00 | General |
| Category: Neuroscience | ||||||
| 12/19/2024 | ABBVIE INC. | BOTOX (Biological), QULIPTA | Food and Beverage | In-kind items and services | $21.14 | General |
| Category: BOTOX THERAPEUTIC | ||||||
| 12/17/2024 | E.R. Squibb & Sons, L.L.C. | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $125.01 | General |
| Category: Neuroscience | ||||||
| 12/14/2024 | EMD Serono, Inc. | — | Food and Beverage | Cash or cash equivalent | $20.89 | General |
| 12/12/2024 | Amgen Inc. | UPLIZNA (Biological) | Food and Beverage | In-kind items and services | $22.45 | General |
| Category: Inflammation/Rare Disease | ||||||
| 12/12/2024 | Celgene Corporation | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $10.69 | General |
| Category: Neuroscience | ||||||
| 12/12/2024 | Amgen Inc. | UPLIZNA (Biological) | Food and Beverage | In-kind items and services | $2.13 | General |
| Category: Inflammation/Rare Disease | ||||||
| 12/11/2024 | Amgen Inc. | UPLIZNA (Biological) | Food and Beverage | In-kind items and services | $20.32 | General |
| Category: Inflammation/Rare Disease | ||||||
| 12/10/2024 | Biogen, Inc. | TYSABRI (Biological) | Food and Beverage | In-kind items and services | $24.79 | General |
| Category: Neurology | ||||||
| 12/06/2024 | Celgene Corporation | ZEPOSIA (Drug) | Travel and Lodging | Cash or cash equivalent | $675.48 | General |
| Category: Neuroscience | ||||||
| 12/06/2024 | Celgene Corporation | ZEPOSIA (Drug) | Travel and Lodging | Cash or cash equivalent | $212.19 | General |
| Category: Neuroscience | ||||||
| 12/06/2024 | Celgene Corporation | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $50.12 | General |
| Category: Neuroscience | ||||||
| 12/06/2024 | Celgene Corporation | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $50.12 | General |
| Category: Neuroscience | ||||||
| 12/06/2024 | Celgene Corporation | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $31.39 | General |
| Category: Neuroscience | ||||||
| 12/06/2024 | Celgene Corporation | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $26.54 | General |
| Category: Neuroscience | ||||||
| 12/06/2024 | Celgene Corporation | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $26.54 | General |
| Category: Neuroscience | ||||||
| 12/05/2024 | PFIZER INC. | NURTEC ODT (Drug), ZAVZPRET | Food and Beverage | In-kind items and services | $26.31 | General |
| Category: PAIN | ||||||
| 12/03/2024 | Genentech USA, Inc. | Ocrevus (Biological), Ocrevus Zunovo | Food and Beverage | In-kind items and services | $17.20 | General |
| Category: Immunology | ||||||
| 12/03/2024 | Teva Pharmaceuticals USA, Inc. | Austedo XR (Drug) | Food and Beverage | In-kind items and services | $16.81 | General |
| Category: Central Nervous System | ||||||
| 12/02/2024 | Genentech USA, Inc. | Ocrevus (Biological), Ocrevus Zunovo | Food and Beverage | In-kind items and services | $33.90 | General |
| Category: Immunology | ||||||
| 11/25/2024 | EMD Serono, Inc. | — | Consulting Fee | Cash or cash equivalent | $695.00 | General |
| 11/23/2024 | EMD Serono, Inc. | — | Food and Beverage | Cash or cash equivalent | $26.68 | General |
| 11/20/2024 | Genentech, Inc. | Ocrevus (Biological) | Food and Beverage | In-kind items and services | $132.09 | General |
| Category: Immunology | ||||||
| 11/18/2024 | TG Therapeutics, Inc. | BRIUMVI (Drug) | Food and Beverage | In-kind items and services | $30.20 | General |
| Category: Immunology | ||||||
| 11/15/2024 | Alexion Pharmaceuticals, Inc. | ULTOMIRIS (Biological) | Food and Beverage | In-kind items and services | $20.08 | General |
| Category: Rare Disease | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 8 | 248 | 550 | $89,475 | $23,144 |
| 2022 | 7 | 231 | 427 | $78,595 | $21,947 |
| 2021 | 5 | 257 | 360 | $99,950 | $28,219 |
| 2020 | 5 | 230 | 28,225 | $81,226 | $21,571 |
Total Patients
966
Total Services
29,562
Medicare Billing
$94,881
Procedure Codes
25
All Medicare Procedures & Services
25 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 106 | 123 | $37,635 | $10,901 | 29.0% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 17 | 100 | $25,400 | $5,178 | 20.4% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 32 | 32 | $12,720 | $4,004 | 31.5% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 29 | 30 | $6,470 | $1,382 | 21.4% |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | Office | 2023 | 18 | 197 | $3,780 | $710.80 | 18.8% |
| 99211 | Office or other outpatient visit for the evaluation and management of established patient that may not require presence of healthcare professional | Office | 2023 | 23 | 24 | $1,355 | $462.99 | 34.2% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2023 | 12 | 12 | $1,635 | $447.02 | 27.3% |
| J7030 | Infusion, normal saline solution , 1000 cc | Office | 2023 | 11 | 32 | $480.00 | $58.56 | 12.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 87 | 96 | $29,555 | $8,678 | 29.4% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 37 | 37 | $15,740 | $5,199 | 33.0% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2022 | 16 | 77 | $19,460 | $4,184 | 21.5% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 38 | 38 | $8,105 | $2,368 | 29.2% |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | Office | 2022 | 15 | 140 | $2,800 | $518.48 | 18.5% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2022 | 12 | 12 | $1,600 | $506.78 | 31.7% |
| 99211 | Office or other outpatient visit for the evaluation and management of established patient that may not require presence of healthcare professional | Office | 2022 | 26 | 27 | $1,335 | $492.43 | 36.9% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 137 | 165 | $51,150 | $15,691 | 30.7% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis up to 1 hour | Office | 2021 | 19 | 94 | $23,500 | $5,108 | 21.7% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 36 | 36 | $16,920 | $4,736 | 28.0% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 34 | 34 | $7,140 | $2,188 | 30.6% |
| 99211 | Established patient outpatient visit, minimal presenting problem | Office | 2021 | 31 | 31 | $1,240 | $496.39 | 40.0% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 153 | 186 | $54,312 | $14,965 | 27.6% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis up to 1 hour | Office | 2020 | 15 | 88 | $20,592 | $4,847 | 23.5% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 28 | 28 | $5,516 | $1,365 | 24.7% |
| 99211 | Established patient office or other outpatient visit, typically 5 minutes | Office | 2020 | 23 | 23 | $805.00 | $393.33 | 48.9% |
| J2323 | Injection, natalizumab, 1 mg | Office | 2020 | 11 | 27,900 | $0.93 | $0.82 | 88.2% |
About Dr. Derek Smith, MD
Dr. Derek Smith, MD is a Neurology healthcare provider based in Norwich, Connecticut. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/14/2006. The National Provider Identifier (NPI) number assigned to this provider is 1407869019.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Derek Smith, MD has received a total of $626,144 in payments from pharmaceutical and medical device companies, with $53,088 received in 2024. These payments were reported across 2,213 transactions from 65 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($385,757).
As a Medicare-enrolled provider, Smith has provided services to 966 Medicare beneficiaries, totaling 29,562 services with total Medicare billing of $94,881. Data is available for 4 years (2020–2023), covering 25 distinct procedure/service records.
Ad
Practice Information
- Specialty Neurology
- Location Norwich, CT
- Active Since 08/14/2006
- Last Updated 07/19/2018
- Taxonomy Code 2084N0400X
- Entity Type Individual
- NPI Number 1407869019
Products in Payments
- TYSABRI (Biological) $76,384
- ZEPOSIA (Drug) $61,422
- TECFIDERA (Drug) $49,741
- Mavenclad (Biological) $47,339
- VUMERITY (Drug) $40,436
- OCREVUS (Biological) $35,526
- Rebif (Biological) $32,506
- BRIUMVI (Drug) $26,571
- AUBAGIO (Drug) $24,694
- MAYZENT (Drug) $22,199
- COPAXONE (Drug) $18,733
- Mavenclad (Drug) $16,800
- Ozanimod (Drug) $13,625
- Evobrutinib $11,815
- Ponvory (Drug) $11,754
- Ocrevus (Biological) $11,040
- ZINBRYTA (Biological) $7,675
- GILENYA (Drug) $6,452
- Betaseron (Drug) $5,759
- DISEASE STATE (Drug) $4,816
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.